Fig. 8From: Effect of Oroxylum indicum on hepatocellular carcinoma via the P53 and VEGF pathways based on microfluidic chipsTube formation in HUVECs a. Control group b. Sorafenib group c. VEGF165 group; d. Low dose group of OI (0.2 mg·mL−1) e. Middle dose group of OI (0.5 mg·mL−1) f. High dose group of OI (0.8 mg·mL.−1)Back to article page